Clicky

Hikma Pharmaceuticals Plc(HIK)

Description: Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.


Keywords: Pharmaceutical Pharmaceutical Products Fentanyl North Africa Strength Supra Argatroban Prograf Generic Injectable Products Hikma Pharmaceuticals

Home Page: www.hikma.com

HIK Technical Analysis

1 New Burlington Place
London, W1S 2HR
United Kingdom
Phone: 44 20 7399 2760


Officers

Name Title
Engineer Said Samih Taleb Darwazah Exec. Chairman & CEO
Mr. Mazen Samih Taleb Darwazah Exec. Vice Chairman & Pres of MENA
Mr. Khalid Waleed Hosny Al Nabilsi Chief Financial Officer
Mr. Hussein Arkhagha Company Sec. & Chief Counsel
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Exec. VP of Corp. Devel. and M&A
Ms. Susan Ringdal Exec. VP of Strategic Planning & Global Affairs
Ms. Majda Labadi Exec. VP of Organisational Devel.
Mr. Riad Mishlawi Pres of Injectables
Mr. Brian Hoffmann Pres of Generics
Mr. Samuel Park Global Head of Intellectual Property (IP) & Gen. Counsel for US

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 9.1491
Trailing PE: 13.1589
Price-to-Book MRQ: 1.8829
Price-to-Sales TTM: 1.2912
IPO Date:
Fiscal Year End: December
Full Time Employees: 8700
Back to stocks